| |
 Program - the 3rd day - Saturday 20th Dec
The password is necessary for the inspection of the first abstract and the second abstract (written in Japanese). For the J-mit and Asian-mit members and pre-registering members, the password to open the abstracts were mailed by the J-mit office or the 8th Annual Conference office of the Japanese Society of Mitochondrial Research and Medicine. The first abstracts are available to print and copy. The second abstracts are neither available to copy nor to print, but only to inspect. Please contact the 8th annual meeting secretariat if you have any inconvenience.
the 1st day - Thu 18th Dec | the 2nd day - Fri 19th Dec| Poster session
Saturday 20th Dec |
9:00 |
Mini Lecture 5 |
|
Overview of Medicine/health food and cancer |
9:15 |
Oral session 8 Cancer |
|
33 ROS-generating mtDNA mutations can regulate tumor cell metastasis. |
|
Kaori Ishikawa1, Keizo Takenaga2, Nobuko Koshikawa3, Miho Akimoto2, Kazuto Nakada1, and Jun-Ichi Hayashi1. (1 Graduate School of Life and Environmental Sciences, University of Tsukuba. 2 Shimane University Faculty of Medicine. 3 Division of Chemotherapy, Chiba Cancer Center Research Institute.)
|
|
34 Mitochondrial function and cell transformation |
|
Masami Watanabe, Hanako Yoshii (Division of radiation Life Science, Research Reactor Institute, Kyoto University)
|
|
35 A mutation in the D-loop region of mitochondrial DNA derived from cancer deteriorate chemosensitivity in cybrid cell lines. |
|
Taku Amo1), Naoto Chihara1,2), Akira Tokunaga2), Ryo Yuzuriha1,2), Alexander M. Wolf1), Sadamitsu Asoh1) and Shigeo Ohta1) (1)Dept. Biochem. Cell. Biol., Inst. Dev. Aging Sci., Gradu. Sch. Med., Nippon Med. Sch. 2)Institute of Gastroenterology, Nippon Medical School Musashikosugi Hospital)
|
|
36 Analysis of mitochondrial energy metabolism in tumor microenvironment as a target of novel anticancer therapy |
|
Eriko Tomitsuka1, Kiyoshi Kita2, Hiroyasu Esumi1 (1Natl. Cancer Center Res. Inst. East, 2Dept. Biomed. Chem., Univ. Tokyo)
|
10:10 |
Oral session 9 Drug reaction |
|
37 SIRT1 Activator Protects against Mitochondrial Toxicity Induced by Nucleoside Reverse Transcriptase Inhibitors in in vitro Models |
|
Akihiko Saitoh1*, Tristan M. Stani1, Robert K. Naviaux2, Neurita G. Salva1, Paul S. Phillips3, Richard H. Haas4 (1Division of Infectious Diseases, Department of Pediatrics, University of California, 2Department of Medicine, University of California San Diego Medical Center, 3Scripps Mercy Clinical Research Center, Scripps Mercy Hospital, Cardiology, Catheterization Laboratories, Scripps Mercy Hospital, 4Depatrtment of Neuroscience and Pediatrics, University of California San Diego Medical Center)
|
|
38 Analyses of sensitivity to MPTP in NDUFV2＋/－ mice |
|
Manabu Funayama1), Satoshi Ohashi2,3), Naoki Ichikawa1), Satoshi Imai1), Shoji Yamamoto2), Hiromichi Kusaka2), Masako Itaya2), Eri Arikawa-Hirasawa1), Yoshikuni Mizuno1), and Nobutaka Hattori1,2) (1)Research Institute for Diseases of Old Ages, and 2)Department of Neurology Juntendo University School of Medicine, 3)Research Unit for Neurological Diseases, Second Institute of New Drug Discovery, Otsuka Pharmaceutical Co., Ltd.)
|
|
39 The mitochondrial toxin, 3-nitropropionic acid induces MUTYH-dependent striatal neurodegeneration with accumulation of 8-oxoguanine which is effectively suppressed by OGG1 and MTH1 |
|
Yusaku Nakabeppu, Zijing Sheng and Sugako Oka (Division of Neurofunctional Genomics, Department of Immunobiology and Neuroscience, Medical Institute of Bioregulation, Kyushu University, Japan)
|
10:50 |
Coffee Break |
11:00 |
Oral session 10 Drug therapy |
|
40 Consumption of molecular hydrogen prevents the impairments in hippocampus-dependent learning tasks induced by physical restraint stress in mice. |
|
Kazufumi Nagata1), Naomi Nakashima-Kamimura1),Toshio Mikami2), Ikuroh Ohsawa1),3), Shigeo Ohta1) (1Dept. Biochem. Cell. Biol., Inst.Dev.Aging Sci., Gradu. Sch. Med., Nippon Med. Sch., 2Dept. Health. Sport. Sci., Nippon Med. Sch. 3Ctr. Mol. Hydro., Inst. Dev. Aging Sci., Nippon Med. Sch)
|
|
41 Species difference in drug-induced mitochondrial permeability transition |
|
Shuichi Sekine, Tomoe Kimura, Midori Motoyama, Yoshihisa Shitara, Toshiharu Horie (Department of Biopharmaceutics. Graduate School of Biopharmaceutical Sciences, Chiba University)
|
|
42 Investigator mediated Phase III open labeled L-arginine clinical trial on MELAS |
|
Koga Y, Katayama K, Povalko N, Iwashita N, Nakamura H, Ohashi Y. (1) Department of Pediatrics and Child Health, Kurume University School of Medicine 2) Clinical Trial Center, Kurume University Hospital 3) Clinical Trial Center, National Center of Child Health and Development, Japan 4) Department of Biostatistics, School of Public Health, University of Tokyo)
|
|
43 Safety and efficacy of pyruvate for Leigh encephalopathy and cardiomyopathy |
|
M. Tanaka, Y. Nishigaki, N. Fuku, H. Wakamoto, Y. Koga, and H. Komaki (Tokyo Metropolitan Institute of Gerontology)
|
11:55 |
Plenary lecture |
|
Proposal by MCM |
|
Ikuya Suginohara (President of the Japanese Organization for Mitochondrial Disease and Their Family) |
12:30 |
Prize Presentation |
12:40 |
Closing Remarks |
12:50 |
Close |
13:30 |
Lecture for MCM |
14:30 |
Lecture with MCM members |
the 1st day - Thu 18th Dec | the 2nd day - Fri 19th Dec | Poster session
|
|
